We reviewed the status of prostate cancer diagnosis in Western Australia (WA) with the aim of improving decision-making about PSA testing and prostate biopsy. Our patient cohort was 5145 men undergoing an initial biopsy for prostate cancer diagnosis in WA between 1998 and 2004. Transrectal ultrasound-guided biopsies were performed by one of 18 clinicians whereas all pathology was assessed by one urological pathologist. Cancer detection rates were 59% for initial biopsies and 32% for repeat biopsies. High-grade cancer (Gleason sum X7) accounted for 69 and 38% of tumours diagnosed on initial and repeat biopsy, respectively. The rates of cancer diagnosis and detection of high-grade tumours were both 1.6-fold higher in WA patients compared with those obtained at baseline screening of the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial of US men (Po0.001). These higher than expected rates of cancer detection and high histological grade indicate that urological practice in WA between 1998 and 2004 was significantly more conservative than US practice over this time period, probably leading to underdiagnosis of prostate cancer. Our findings may be relevant to other countries where urological practice differs from that in the United States.
Introduction
The 2009 PSA testing policy 1 recently released by the Urological Society of Australia and New Zealand (USANZ) closely mirrors guidelines in the ProstateSpecific Antigen Best Practice Statement: 2009 Update 2 by the American Urological Association (AUA). Both publications warn that the survival benefit of early prostate cancer detection through PSA testing remains unproven, although there is sufficient evidence to justify the use of PSA testing and digital rectal examination (DRE) for well-informed men who wish to pursue early diagnosis and who have sufficient life expectancy to benefit from this. Furthermore, both groups caution that the decision to proceed to prostate biopsy should be based on multiple factors including DRE findings, age, family history, comorbidities and use of age-specific PSA ranges, PSA velocity and free to total PSA ratios. These recommendations are formulated to prevent excessive expense and patient morbidity that may arise through overdiagnosis and overtreatment in the setting of indiscriminate population-based prostate cancer screening.
The subject of PSA testing and the potential for overdiagnosis of prostate cancer have been the focus of considerable media attention in Australia following the 2009 publication of two large international trials; the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial of US men 3 and the European Randomized Study of Screening for Prostate Cancer (ERSPC). 4 These trials have been commonly interpreted in the media as showing little or no mortality benefit from PSA screening at the risk of considerable overdiagnosis, overtreatment and morbidity. The media debate has been further exacerbated by the recent AUA and USANZ decision to lower the recommended age for obtaining a baseline PSA level from 50 to 40 years. 1, 2 In this current setting Australian men, general practitioners and urologists make decisions regarding the use of PSA testing and prostate biopsy based on published international data, which may not reflect actual medical practice in Australia. Our study aims to address the almost total lack of published Australian data, presenting an analysis of 5145 Western Australian (WA) men who underwent prostate biopsy for cancer diagnosis between 1998 and 2004. We assess our detection rates of cancer and highgrade cancer at initial and at repeat biopsy, and compare our findings to those obtained at baseline screening of the PLCO cohort. Our results suggest that Australian urological practice was significantly more conservative than American urological practice over this time period and that Australian men may be at risk of underdiagnosis of prostate cancer.
Materials and methods
We reviewed all 5775 consecutive patients entered in the West Australian Prostate Biopsy Database between September 1998 and September 2004. These represent approximately 85% of all public and private biopsies performed in WA over this time period, as determined by comparison of our case numbers with WA medicare data for transrectal ultrasound (TRUS)-guided prostate biopsy. Patients were excluded if they had any previous diagnosis of prostate cancer, previous biopsy results from another pathology provider, or if biopsy revealed cancer of non-prostatic origin, leaving 5145 men who were undergoing initial biopsy for prostate cancer diagnosis. Biopsies were performed by one of 18 clinicians, each conducting varying biopsy schemes in terms of needle core number, placement and method (transrectal or transperineal). All needle biopsies and radical prostatectomy specimens were assessed by one urological pathologist (RJC; Uropath).
The pathological characteristics of tumours detected at initial versus repeat biopsy were compared using biopsy data for all 3225 men with cancer diagnosed at biopsy. For 1442 cases where both a preoperative PSA value and a TRUS-calculated prostate volume were available, tumours were classified as clinically insignificant cancer based on the contemporary Epstein criteria of PSA density o0.15 ng ml -1 , no more than two cores positive for carcinoma, no core with greater than 50% cancer involvement, and Gleason sum p6. 5 Comparison of tumours detected at initial versus repeat biopsy was also performed using radical prostatectomy data for the patients who progressed to surgery. Although 898 patients underwent prostatectomy, we excluded those who had pre-operative hormone ablation therapy (the practice of one urologist) or cancer diagnosis based on findings at TURP, leaving 818 men for this analysis. For radical prostatectomy cases, clinically insignificant cancer was defined using the postoperative Epstein criteria of tumour volume p0.5 cc, Gleason sum p6 and organ confined. 6 This research was approved by the Hollywood Private Hospital Research Ethics Committee (HPH132/128).
All statistical analyses were performed using SPSS 17.0 for Windows. Parameters were compared between groups using non-parametric methods; the KruskalWallis test for continuous variables and the w 2 test for categorical variables. All P-values were two-sided with statistical significance accepted as Po0.05.
Results
Descriptive statistics for the 5145 men who underwent an initial needle core biopsy for prostate cancer diagnosis are shown in To determine if cancers detected on initial and repeat biopsy differed in clinical relevance, we then compared the clinicopathological characteristics of these tumours. Comparisons using parameters determined at biopsy are shown in Table 2 . The median number of needle cores taken increased significantly from eight cores in initial biopsies to 13 cores in third or further biopsy procedures. Men with cancer diagnosed on repeat biopsy were significantly younger at the time of initial biopsy, with significantly lower PSA levels but larger prostate glands as determined by TRUS. Tumours detected on repeat biopsy were significantly lower in grade (as determined by Gleason sum and the percent of tumour with Gleason sum 4 and/or 5) and more likely to meet the preoperative Epstein criteria for insignificant cancer (see Materials and methods). However, cancer graded as Gleason sum 7 or higher still accounted for over a third of cases diagnosed on second (37.7%) or further (38.4%) biopsy procedures ( Table 2) . Comparisons using parameters determined at radical prostatectomy were performed for the subset of 818 men selected for surgical treatment who had complete data available for analysis (Table 3) . The trends of larger prostates and higher proportions of tumours meeting the post-operative Epstein criteria for insignificant cancer (see Materials and methods) were still statistically significant in men diagnosed on repeat biopsy, however, the trends towards younger age, lower PSA levels and lower tumour grades were less prominent, most likely reflecting the criteria used to select these patients for surgical treatment. Notably, the index tumours in men diagnosed on repeat biopsy were significantly more likely to be smaller in volume, of transition zone origin and organ-confined, although the positive surgical margin rate was not significantly lower in these cases (Table 3) . Finally, we compared our WA prostate biopsy data for men aged 55-74 years to data from baseline (prevalence) screening in the PLCO cancer screening trial of US men. 7 The rates of cancer diagnosis and detection of high-grade tumours (Gleason sum X7) were both 1.6-fold higher in WA patients compared with PLCO men (Po0.001; Table 4 ). Furthermore, these higher rates were apparent within every stratification of PSA levels up to PSA 410 ng ml -1 (Table 4 ).
Discussion
Our study presents an overview of WA men undergoing prostate biopsy between 1998 and 2004. Cancer detection rates were 59% for initial biopsies and fell to 32% for repeat biopsies. Over two-thirds of tumours diagnosed on initial biopsy and one-third of tumours diagnosed on repeat biopsy were high grade (Gleason sum X7). Finally, we showed that the rates of cancer diagnosis and detection of high-grade tumours in WA men were 1.6-fold higher than those determined at baseline screening in the PLCO study.
Comparison of positive biopsy rates and percent of high-grade tumours between different patient populations should consider three major factors that influence these rates, the first of which is the degree of screening for prostate cancer in the study population. Although PSA testing is common in the USA, the PLCO trial excluded men currently undergoing annual PSA testing, enrolling a baseline population in which 44% of men had been tested within the previous 3 years but only 9.4% had undergone more than one test in that time. , no more than two cores positive for carcinoma, no core with greater than 50% cancer involvement, and Gleason sum p6.
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Although there is little data published for Australia, a 1998 survey reported that 43% of asymptomatic WA men aged over 40 years had undergone at least one PSA test, 8 which is consistent with a 2003 survey reporting that 49% of Australian men aged over 40 years had previously undergone at least one PSA test. 9 Thus our Australian population appears fairly comparable with the PLCO cohort at baseline in regard to degree of previous screening.
The second factor to consider is the proportion of men with suspicious screen tests who undergo biopsy. As shown by the ERSPC study, 10 biopsy of the majority of men with suspicious screen tests yields a lower proportion of positive biopsies and high grade tumours due to increased sampling of men with false-positive tests or minimal disease. In the PLCO trial all men with suspicious tests (PSA X4 ng ml -1 and/or suspicious DRE findings) were referred to their private care physicians for diagnostic workup, with only 31.5% progressing to biopsy by 1 year after initial screening. 7 Although we have no information on the proportion of WA men with suspicious screening tests who underwent biopsy, our WA patients are again comparable with the PLCO cohort in that progression to biopsy was determined by multiple physicians using independent clinical judgement. Our higher rates of positive biopsies and high-grade tumours suggest that a lower proportion of WA men with suspicious screening results progressed to biopsy than in the PLCO trial. More stringent selection of patients progressing to biopsy may also explain the higher grade of detected cancer compared with PLCO patients. Variation in Gleason grading between different pathologists may also have a minor role because all of our WA specimens were assessed by a single urological pathologist. It has been shown that urological pathologists consistently assign higher Gleason grades than The third factor to consider is the biopsy protocols used. As lateralized sextant biopsy was the gold standard protocol in the United States between 1995 and 2000, 12 it is likely that the majority of first round biopsies in the PLCO (conducted between 1993 and 2001) would have used this scheme. Similarly, the most common biopsy protocols used by our urologists between 1998 and 2004 were lateralized sextant and lateralized sextant plus two cores into the transition zone, with one practitioner using an 11-13 core transperineal procedure (data not shown). Our predominant use of sextant biopsy may also explain our relatively high (32%) yield of cancer on repeat biopsy, because cancer detection rates of 39% have been shown following a previous negative sextant biopsy compared with 28% after previous negative extended biopsy. 13 Thus after consideration of the above factors, it appears likely that the high positive biopsy rate and predominant detection of high-grade tumours shown here for WA prostate biopsy patients is largely reflecting highly conservative medical practice, either in terms of referral to urologists after suspicious screening tests and/or selection of referred patients for prostate biopsy. A similarly high positive prostate biopsy rate (51.4%) was reported for a cohort of Australian patients in Sydney, New South Wales between 1995 and 2003, with the authors attributing their findings to 'super-selection' of patients progressing to biopsy.
14 A limitation of our study is that we do not know exactly what criteria were used in selecting patients for prostate biopsy. However, the low proportions of biopsy patients with PSA p4.0 in WA (7.3%; Table 4 ) and New South Wales (5.8%) 14 compared with PLCO (26.3%; Table 4 ) patients suggest that Australian urologists in general were less likely to perform biopsy on men with lower PSA levels. This may explain why our positive biopsy rates were only higher compared with PLCO patients within PSA stratifications up to 10 ng ml -1 . Interestingly, analysis of patients referred to a public hospital in South Australia for prostate biopsy between 1998 and 2005 revealed that general practitioners had monitored patients with abnormal PSA levels below 10 ng ml -1 (median of 5.7 ng ml -1 ) for at least 6 months before referral, with a delay longer than 20 months reported for 25% of these men. 25 As discussed earlier, no annual rates have been published for Australia but a 2003 survey reported that 49% of Australian men aged over 40 years had previously undergone at least one PSA test. 9 This figure is very similar to Canadian data showing that 43% of men aged over 40 years in 2001 had previously undergone at least one PSA test. 26 In addition to a comparatively low rate of PSA screening, the study from Italy (Tuscany) reported that only 15.5% of men with PSA X4.0 ng ml -1 progressed to prostate biopsy and concluded that this rate Prostate biopsy in Western Australia BA O'Brien et al was too low to realize any potential gain from PSA screening. 24 In conclusion, our results suggest that general practitioner/urologic practice in WA between 1998 and 2004 was significantly more conservative than US practice over that time period, possibly leading to underdiagnosis of prostate cancer. It is likely that this situation still exists, and this matter will be addressed in future publications once the retrospective entry of current data into our prostate biopsy database is complete. This finding is highly relevant given the recent publicity debates on overdiagnosis associated with PSA screening following publication of mortality trends for the PLCO and ERSPC trials. In fact our results suggest that a higher proportion of men with suspicious screening tests in WA, and perhaps all of Australia, should undergo prostate biopsy. It is important to note that while the high biopsy rate of the ERSPC (85.8% of men with PSA X3.0 ng ml -1 ) led to a level of overdiagnosis estimated to be as high as 50%, 4 this problem would be reduced by selecting patients for biopsy based on multiple factors as recommended by current AUA 2 and USANZ 1 urological guidelines (DRE, age, family history, comorbidities, age-specific PSA, PSA velocity and free to total PSA ratios), rather than a single elevated PSA reading as specified in the screening study. By contrast, the lower biopsy rate in the PLCO trial (30.1-40.2%) 27 indicates that there is less risk of overdiagnosis if progression to biopsy is determined according to urological practice guidelines. The failure of the PLCO study to show a reduction in prostate cancerspecific mortality is likely to reflect the considerable degree of contamination in their control arm (an opportunistic PSA screening rate of 40-52%) and the relatively short median follow-up time of 5.2-6.3 years at publication. 3 By contrast, the 20% reduction in prostate cancer-specific mortality shown for the ERSPC screening arm may reflect multiple factors in addition to the high rate of prostate biopsy, in particular the longer median follow-up time of 8.8-9.0 years, because the survival curves for the screening and control arms only began to separate after 7-8 years of follow-up. 4 A third relevant factor may be the lower degree of contamination in the ERSPC control arm. Figures for the entire study are not known but opportunistic PSA screening rates were 30.7% for the Rotterdam section 28 and 27.8% for the Spanish section. 29 It therefore seems possible that clinicians could improve prostate cancer diagnosis and mortality in Australia by (i) promptly referring more men with suspicious screening tests to urologists and (ii) performing TRUS biopsies on a larger proportion of these men (selected according to USANZ 1 urologic guidelines), without increasing the risk of overdiagnosis to the degree reported in the ERSPC study.
